Amylyx Pharmaceuticals Stock

$6.76

7.30%

NYSE, Jul 07, 10:00 pm CET

ISIN

US03237H1014

Symbol

AMLX

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Amylyx Pharmaceuticals Stock price

$6.76

-11.31 62.59% 5Y

NYSE, Closing price Mon, Jul 07 2025

+0.46 7.30%

ISIN

US03237H1014

Symbol

AMLX

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$561.6m

Enterprise Value

$357.5m

Net debt

positive

Cash

$204.1m

Shares outstanding

89.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

negative | -

EV/FCF

negative

P/B

2.8

Financial Health

Equity Ratio

85.1%

Return on Equity

-183.1%

ROCE

-114.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$-610.0k | $0.0

EBITDA

$-229.7m | $-132.5m

EBIT

$-230.4m | $-164.3m

Net Income

$-218.9m | $-162.6m

Free Cash Flow

$-243.3m

Growth (TTM | estimate)

Revenue

-100.2% | -100.0%

EBITDA

-1,949.1% | 18.4%

EBIT

-2,152.6% | -

Net Income

-207.8% | 46.1%

Free Cash Flow

-1,675.7%

EPS

$-2.6

FCF per Share

$-2.7

Short interest

5.0%

Employees

384

Rev per Employee

$230.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Amylyx Pharmaceuticals forecast:

13x Buy

87%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy

87%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	-0.61 -0.61	100% 100% 100%
- Direct Costs	8.23 8.23	81% 81% -
Gross Profit	-8.83 -8.83	102% 102% -
- Selling and Administrative Expenses	72 72	64% 64% -
- Research and Development Expense	90 90	36% 36% -
EBITDA	-230 -230	1,949% 1,949% -
- Depreciation and Amortization	0.75 0.75	38% 38% -
EBIT (Operating Income) EBIT	-230 -230	2,153% 2,153% -
Net Profit	-219 -219	208% 208% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amylyx Pharmaceuticals Stock News

Positive

The Motley Fool

●

11 days ago

Why Shares in Amylyx Pharmaceuticals Soared This Week

Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.

Neutral

GlobeNewsWire

●

26 days ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

Neutral

Business Wire

●

about one month ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis.

More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Josh Klee
Employees	384
Founded	2013
Website	www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now